<DOC>
	<DOCNO>NCT02451943</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy combination doxorubicin plus study drug know olaratumab versus doxorubicin plus placebo participant advance metastatic soft tissue sarcoma .</brief_summary>
	<brief_title>A Study Doxorubicin Plus Olaratumab ( LY3012207 ) Participants With Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Histologically confirm diagnosis advance unresectable metastatic soft tissue sarcoma amenable curative treatment surgery radiotherapy . Participants Kaposi 's sarcoma gastrointestinal stromal tumor ( GIST ) exclude . Note : Evidence disease progression require participant newly diagnose . Presence measurable nonmeasurable evaluable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 , Eisenhauer et al . 2009 ) . Performance status 01 Eastern Cooperative Oncology Group ( ECOG ) scale . The participant receive previous treatment anthracyclines . The participant may number prior systemic cytotoxic therapy advanced/metastatic disease consider appropriate candidate anthracycline therapy . All previous anticancer treatment must complete ≥ 3 week ( 21 day ) prior first dose study drug . Availability tumor tissue require study eligibility . The participant must consent provide archive formalinfixed paraffin embed ( FFPE ) tumor tissue subject pretreatment rebiopsy primary metastatic tumor tissue future central pathology review translational research ( archived tissue unavailable ) . Adequate hematologic , organ , coagulation within 2 week ( 14 day ) prior randomization . Left ventricular ejection fraction ( LVEF ) ≥50 % assess within 28 day prior randomization . Females childbearing potential must negative serum pregnancy test within 7 day prior randomization . Females childbearing potential male must agree use highly effective contraceptive precaution trial 3 month follow last dose study drug . The participant , opinion investigator , life expectancy least 3 month . Diagnosis GIST Kaposi sarcoma . Active central nervous system ( CNS ) leptomeningeal metastasis ( brain metastasis ) time randomization . Participants history CNS metastasis previously treat curative intent ( example , stereotactic radiation surgery ) progress followup imaging , asymptomatic least 60 day receive systemic corticosteroid or/anticonvulsants , eligible . Participants sign symptom neurological compromise appropriate radiographic imaging perform randomization rule brain metastasis . Prior treatment doxorubicin , epirubicin , idarubicin , and/or anthracyclines anthracenediones ; participant receive treatment olaratumab participate prior olaratumab trial . Prior radiotherapy mediastinal/pericardial area whole pelvis radiation . The participant symptomatic congestive heart failure ( CHF ) , leave ventricular dysfunction ( LVEF &lt; 50 % ) , severe myocardial insufficiency , cardiac arrhythmia , cardiomyopathy . The participant unstable angina pectoris , angioplasty , cardiac stenting , myocardial infarction within 6 month randomization . The participant QT interval calculate use Bazett 's formula ( QTcB ) interval &gt; 450 millisecond ( msec ) males &gt; 470 msec female screen electrocardiogram ( ECG ) . Females pregnant breastfeeding . Known allergy treatment component include history allergic reaction attribute compound chemical biological composition similar olaratumab . The participant know active fungal , bacterial , viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>leiomyosarcoma</keyword>
	<keyword>soft tissue sarcoma ( STS )</keyword>
	<keyword>advanced soft tissue sarcoma</keyword>
	<keyword>metastatic soft tissue sarcoma</keyword>
	<keyword>liposarcoma</keyword>
	<keyword>undifferentiated pleomorphic sarcoma</keyword>
	<keyword>doxorubicin</keyword>
</DOC>